Tag: sitagliptin
-
Potential Safety Signal: Rhabdomyolysis May Be Linked To Onglyza, Nesina, Januvia, And Other Diabetes Drugs
FDA Was Already Investigating The Dipeptidyl Peptidase IV (DPP-IV) Inhibitor Class Of Diabetes Drugs For Kidney Or Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) According to a new FDA quarterly report,…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Pancreatic Cancer As A Side Effect Of Diabetes Drugs Bydureon, Byetta, Januvia, And Victoza
Health Canada Currently Conducting Epidemiological Study Of These Incretin-Based Type 2 Diabetes Medications To Assess This Potential Drug Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com)From the October 2014 edition of the Canadian Adverse Reaction Newsletter we…
-
Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza — Little Is Known About Long-Term Effects
As “Pancreatitis Is On The Pathway Toward Pancreatic Cancer”, Medical Studies Needed To Determine If GLP-1 Diabetes Medications Linked To Cancers Or Malignancies Involving Pancreas (Posted by Tom Lamb at DrugInjuryWatch.com)______________________________________________________________________________ UPDATE: “Cancer of The Pancreas:…
-
Acute Pancreatitis Case Associated With Victoza Use, Similar To Byetta And Januvia Case Reports
Drug Safety Issue Controversy Continues: True Serious Side Effect, Or Attributable To Type 2 Diabetes Condition (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: Victoza (liraglutide [rDNA origin]) Injection: REMS – Risk of Thyroid…
-
FDA Wants Merck To Change Januvia Label With Increased Warning About Pancreatitis Risk
Is Januvia Similar To Byetta In Terms Of The So-Called Class Effect And Drug Injury Lawsuits Being Filed? (Posted by Tom Lamb at DrugInjuryWatch.com) On September 25, 2009 the FDA posted on its web…